

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT			
NATURE OF CONVEYANCE:	SECURITY INTEREST			
CONVEYING PARTY DATA				
	Name	Formerly	Execution Date	Entity Type
	POLYMEDIX, INC.		01/16/2013	CORPORATION: DELAWARE
	POLYMEDIX PHARMACEUTICALS, INC.		01/16/2013	CORPORATION: DELAWARE
RECEIVING PARTY DATA				
Name:	MIDCAP FINANCIAL SBIC, LP, as Administrative Agent			
Street Address:	7255 Woodmont Avenue, Suite 200			
City:	Bethesda			
State/Country:	MARYLAND			
Postal Code:	20814			
Entity Type:	LIMITED PARTNERSHIP: DELAWARE			
PROPERTY NUMBERS Total: 9				
	Property Type	Number	Word Mark	
	Registration Number:	3729726	GOLDYN	
	Registration Number:	3538219	P POLYMEDIX	
	Registration Number:	3729727	PACE	
	Registration Number:	4118719	POLYCIDE	
	Registration Number:	3887304	POLYCIDE	
	Registration Number:	4063543	POLYDENTIX	
	Serial Number:	85388529	POLYDENTIX	
	Registration Number:	3401024	POLYMEDIX	
	Registration Number:	3729728	SUCCEED	
CORRESPONDENCE DATA				
Fax Number:	3126095005			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>				

CH \$240.00 3729726

Phone: 312-609-7943
Email: skowalski@vedderprice.com
Correspondent Name: Sylvia Kowalski
Address Line 1: 222 North LaSalle Street - 24th Floor
Address Line 4: Chicago, ILLINOIS 60601

ATTORNEY DOCKET NUMBER:	41012.00.0074 - SULLIVAN
NAME OF SUBMITTER:	Sylvia Kowalski
Signature:	/Sylvia Kowalski/
Date:	01/17/2013

Total Attachments: 16

source=IP Security Agreement_1#page1.tif
source=IP Security Agreement_1#page2.tif
source=IP Security Agreement_1#page3.tif
source=IP Security Agreement_1#page4.tif
source=IP Security Agreement_1#page5.tif
source=IP Security Agreement_1#page6.tif
source=IP Security Agreement_1#page7.tif
source=IP Security Agreement_1#page8.tif
source=IP Security Agreement_1#page9.tif
source=IP Security Agreement_1#page10.tif
source=IP Security Agreement_1#page11.tif
source=IP Security Agreement_1#page12.tif
source=IP Security Agreement_1#page13.tif
source=IP Security Agreement_1#page14.tif
source=IP Security Agreement_1#page15.tif
source=IP Security Agreement_1#page16.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the 16th day of January, 2013 by and between MIDCAP FINANCIAL SBIC, LP, a Delaware limited partnership, as administrative agent (in such capacity, "**Administrative Agent**") for certain lenders (the "**Lenders**"), and POLYMEDIX, INC., a Delaware corporation, and POLYMEDIX PHARMACEUTICALS, INC., a Delaware corporation (collectively, the "**Grantor**").

RECITALS

A. The Lenders have agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "**Loans**") in the amounts and manner set forth in that certain Loan and Security Agreement by and among Administrative Agent, the Lenders and Grantor dated as of April 5, 2012 (as the same may be amended, modified or supplemented from time to time, the "**Loan Agreement**"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to continue to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Administrative Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, and Patents (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Administrative Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

C. PolyMedix Pharmaceuticals, Inc. was incorporated on August 8, 2002, under the name "PolyMedix, Inc." On February 24, 2006, it changed its name to "PolyMedix Pharmaceuticals, Inc." and PolyMedix, Inc. (formerly, "BTHC II Acquisition Corp.") adopted the "PolyMedix, Inc." name.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Administrative Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "**Intellectual Property Collateral**"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret,

now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(g) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(h) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and

(i) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Administrative Agent, for the ratable benefit of the Lenders, under the Loan Agreement. The rights and remedies of Administrative Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Administrative Agent as a matter of law or equity. Each right, power and remedy of Administrative Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Administrative Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Administrative Agent, of

any or all other rights, powers or remedies. THIS AGREEMENT, AND ALL MATTERS RELATING HERETO ARISING HEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.

[Signature page follows.]

(Signature Page to Intellectual Property Security Agreement)


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

**POLYMEDIX PHARMACEUTICALS,
INC., a Delaware corporation**

c/o PolyMedix Pharmaceuticals, Inc.
170 N. Radnor Chester Road, Suite 300
Radnor, Pennsylvania 19807
Attention: Edward Smith,
Chief Financial Officer
Fax: (484) 598-2333
E-Mail: esmith@polymedix.com

By: 
Edward F. Smith
Vice President, Chief Financial
Officer and Secretary

CHICAGO/#2405760

**TRADEMARK
REEL: 004945 FRAME: 0408**

(Signature Page to Intellectual Property Security Agreement)

Address of Grantor:

c/o PolyMedix Pharmaceuticals, Inc.
170 N. Radnor Chester Road, Suite 300
Radnor, Pennsylvania 19807
Attention: Edward Smith,
Chief Financial Officer
Fax: (484) 598-2333
E-Mail: esmith@polymedix.com

GRANTOR:

POLYMEDIX, INC., a Delaware
corporation

By: 

Edward F. Smith
Vice President, Chief Financial
Officer and Secretary

(Signature Page to Intellectual Property Security Agreement)

Address of Administrative Agent:

MidCap Financial SBIC, LP
7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attention: Portfolio Management- Life
Sciences
Fax: (301) 941-1450
E-Mail: lviera@midcapfinancial.com

with a copy to:

Midcap Financial, LLC
7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attention: General Counsel
Fax: (301) 941-1450
E-Mail: rgoodridge@midcapfinancial.com

ADMINISTRATIVE AGENT:

MIDCAP FINANCIAL SBIC, LP, a
Delaware limited partnership

By: MIDCAP FINANCIAL SBIC GP,
LLC, a Delaware limited liability
company
Its: General Partner


By: 
Luis Viera
Authorized Signatory

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

Borrower	Name/Identifier of IP	Type of IP	Expiration Date
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (1)	Design, preparation and properties of antibacterial beta-peptides - US Patent 6,677,431.*	Patent	2020
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (1)	Amphiphilic Polymers as Anti-Infective Agents - Filed US (10/471,028) and PCT (PCT/US02/022043). <ul style="list-style-type: none"> - US Patent 7,173,102 - EP patent 1372551 - Other issued patents: Australia, China, Japan, South Korea Divisional filings <ul style="list-style-type: none"> - Canada 	Patent	2022
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (1)	Amphiphilic Polymers as Anti-Infective Agents – Filed US (10/471,029) and PCT (PCT/US02/006899). <ul style="list-style-type: none"> - EP patent 1372674 - Other issued patents: Australia, South Korea Divisional filings <ul style="list-style-type: none"> - EP (100009912.6) - Others: Japan, China 	Patent	2022
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (1)	Facially amphiphilic polymers and oligomers and uses thereof - Filed US (10/801,951, 13/559,065) and PCT (PCT/US04/008155). <ul style="list-style-type: none"> - Other issued patents: Australia Divisional filings <ul style="list-style-type: none"> - US (11/980,785); Granted US Patent 8,236,800 - EP (4: 12000366.0, 12000364.5, 12000363.7, 12000362.9) - Others: Australia, China, Japan 	Patent	2024

<u>Borrower</u>	<u>Name/Identifier of IP</u>	<u>Type of IP</u>	<u>Expiration Date</u>
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (1)	<p>Facially amphiphilic polymers and oligomers and uses thereof – Filed US (11/038,787) and PCT (PCT/US05/001885).</p> <ul style="list-style-type: none"> - US Patent 8,222,456 - Other issued patents: Australia <p>Divisional filings</p> <ul style="list-style-type: none"> - US (13/365,840) - EP (12000444.5) - Others: China, South Korea 	Patent	2025
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.)	<p>Polycationic Compounds and Uses thereof - Filed US (11/154,962) and PCT (PCT/US05/21323)</p> <ul style="list-style-type: none"> - US Patent 7,553,876 - China, Australia, South Korea <p>US Continuation (12/465,995)</p> <ul style="list-style-type: none"> - US patent 7,745,662 <p>US Continuation (12/720,734)</p> <ul style="list-style-type: none"> - US patent 8,232,428 <p>US Continuation (12/971,006)</p> <ul style="list-style-type: none"> - US patent 8,129,566 <p>US Continuation (13/529,249)</p> <p>Divisional filings</p> <ul style="list-style-type: none"> - EP (11171395.4) - Others: Japan, China, South Korea (patent issued) 	Patent	2025
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (1)	<p>Facially Amphiphilic Polymers And Oligomers, Compositions Thereof, And Uses Thereof In Methods Of Treating Cancer – Filed US (11/361,050) and PCT (PCT/US06/006487).</p> <p>Divisional filings</p> <ul style="list-style-type: none"> - EP (3: 10015892.2, 11010096.3, 11010095.5) - Others: Australia, Taiwan 	Patent	2026
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (1)	<p>Antimicrobial Copolymers And Uses Thereof - Filed US (11/186,942) and PCT (PCT/US05/026188)*</p> <ul style="list-style-type: none"> - Issued patents: Australia <p>Divisional filings</p> <ul style="list-style-type: none"> - EP (11000960.2) - Others: Japan 	Patent	2025

Borrower	Name/Identifier of IP	Type of IP	Expiration Date
PolyMedix, Inc.	Ophthalmic and Otic Compositions of Facially Amphiphilic Polymers and Oligomers and Use Thereof - Filed US (11/965,194) and PCT (PCT/US07/89001). - Issued patents: China Divisional filings - US (13/661,466) - China	Patent	2027
PolyMedix, Inc. (4)	Combination of Synthetic Antimicrobial Polymers and Sesquiterpenoid Compounds - Filed US only (12/191,601).*	Patent	2028
PolyMedix, Inc.	Anti-Malarial Compounds - Filed US (12/510,593) and PCT (PCT/US09/51909).*	Patent	2029
PolyMedix, Inc.	Synthetic Mimetics of Host Defense and Uses Thereof - Filed US (12/605,584) and PCT (PCT/US09/62147). - US Patent 8,278,309 Divisional filings - US (13/563,928)	Patent	2029
PolyMedix, Inc.	Antimicrobial Molecules for Treating Multi-Drug Resistant and Extensively-Drug Resistant Strains of Mycobacterium - Filed US (12/633,971) and PCT (PCT/US09/67388). Divisional filings - US (13/657,976)	Patent	2029
PolyMedix, Inc. (3)	Antimicrobial Polymers - Filed US (12/795,892) and PCT (PCT/US10/37685). - US Patent 8,153,739 Divisional filings - US (13/441,114)	Patent	2030
PolyMedix, Inc.	Processes for Preparing a Polymeric Compound - Filed US (12/908,977) and PCT (PCT/US10/53546). - US Patent 8,354,556 Divisional filings - US (13/720,298)	Patent	2030
PolyMedix, Inc.	Anti-Heparin Compounds - Filed US (12/984,634) and PCT (PCT/US11/20162)	Patent	2031
PolyMedix, Inc. (5)	Methods of Immune Modulation - Filed US (13/177,056) and PCT (PCT/US11/43020).	Patent	2031
PolyMedix, Inc.	Facially Amphiphilic Compounds, Compositions, and Uses Thereof in Treating Cancer - Filed US (13/214,177) and PCT (PCT/US11/48530).*	Patent	2031

Borrower	Name/Identifier of IP	Type of IP	Expiration Date
PolyMedix, Inc.	Compounds For Use In Treatment Of Mucositis – Filed US (13/471,689) and PCT (PCT/US12/37895).	Patent	2032
PolyMedix, Inc.	Cyclic compounds and methods of making and using the same- Filed US and PCT (PCT/US12/68722).	Patent	2032
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (2)	Methods, systems and computer program products for computational analysis and design of amphiphilic polymers - US Patent 7,590,517.*	Patent	2023
PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) (2)	Computer simulation of biomembranes using a Coarse Grain Model - US Patent 8,234,074.*	Patent	2023

Key:

- (1) Patents subject to the Patent License Agreement, dated January 3, 2003, by and between The Trustees of the University of Pennsylvania and PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.), as amended by the Letter Agreement, dated December 23, 2003.
- (2) Patents subject to Software License Agreement, dated May 30, 2003, by and between The Trustees of the University of Pennsylvania and PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.).
- (3) Patents subject to the Exclusive License Agreement, dated January 2, 2005, by and between the University of Massachusetts and PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.).
- (4) Co-owned with Iowa State University research Foundation.
- (5) Co-owned with University of Medicine and Dentistry of New Jersey.

EXHIBIT C

Trademarks

<u>Trademark/ Country</u>	<u>Goods</u>	<u>Application Number/Date</u>	<u>Publication Number/Date</u>	<u>Registration Number/Date</u>	<u>Status/ Next Renewal</u>
POLYDENTIX* China	Class: 05 Int. - Antimicrobial preparations, biotechnologically and synthetically- developed therapeutic agents, and antimicrobial agents for dental use	6394055 22 Nov 2007	27 Dec 2009	6394055 28 Mar 2010	Registered 27 Mar 2020
POLYMEDIX* China	Class: 05 Int. - Therapeutic preparations interacting with cellular membranes or proteins, namely for use in treating antimicrobial and cardiac diseases or disorders; synthetically developed therapeutic agents for antimicrobial or acute cardiovascular use	6432635 12 Dec 2007	27 Dec 2009	6432635 28 Mar 2010	Registered 27 Mar 2020
POLYCIDES* European Community	Class: 05 Int. - Antimicrobial preparations, blends and formulations of oligomers and small molecules used to treat, eliminate and/or reduce the growth of bacteria and fungus on various surfaces	010754497 23 Mar 2012			Pending

<u>Trademark/ Country</u>	<u>Goods</u>	<u>Application Number/Date</u>	<u>Publication Number/Date</u>	<u>Registration Number/Date</u>	<u>Status/ Next Renewal</u>
POLYMEDIX* European Community	Class: 05 Int. - Therapeutic preparations interacting with cellular membranes or proteins, namely, for use in treating antimicrobial and cardiac diseases or disorders; synthetically developed therapeutic agents, and antimicrobial or acute cardiovascular use Class: 42 Int. - Development of pharmaceutical preparations and medicines; medical pharmaceutical and biotechnology research and development services	6417621 08 Nov 2007	22 Sep 2008	006417621 17 Mar 2009	Registered 08 Nov 2017
POLYDENTIX* Japan	Class: 05 Int. - Pharmaceutical; therapeutic antimicrobial preparations, biotechnologically and synthetically- developed therapeutic agents, and antimicrobial agents for dental use	2007117649 22-Nov-2007		5130391 18 Apr 2008	Registered 18 Apr 2018

<u>Trademark/ Country</u>	<u>Goods</u>	<u>Application Number/Date</u>	<u>Publication Number/Date</u>	<u>Registration Number/Date</u>	<u>Status/ Next Renewal</u>
POLYMEDIX* Japan	Class: 05 Int. - Pharmaceuticals; pharmaceutical preparations for use in treating antimicrobial and cardiac diseases or disorders by interacting with cellular membranes or proteins, synthetically developed therapeutic agents for use in treating anti-infective and acute cardiovascular diseases and disorders	2007117648 22 Nov 2007		5154453 25 Jul 2008	Registered 25 Jul 2018
POLYCIDE* Russian Federation	Class: 05 Int. - Antimicrobial preparations, blends and formulations of oligomers and small molecules used to treat, eliminate and/or reduce the growth of bacteria and fungus on various surfaces	2012708862 26 Mar 2012			Pending
GOLDYN* United States	Class: 42 Int. - Providing on-line non-downloadable computer software for use in the research and development of therapeutic drug preparations	77/611100 10 Nov 2008	24 Mar 2009	3729726 22 Dec 2009	Registered 22 Dec 2019

<u>Trademark/ Country</u>	<u>Goods</u>	<u>Application Number/Date</u>	<u>Publication Number/Date</u>	<u>Registration Number/Date</u>	<u>Status/ Next Renewal</u>
P POLYMEDIX & Design* United States	Class: 05 Int. Therapeutic preparations interacting with cellular membranes or proteins, namely for use in treating antimicrobial and cardiac diseases or disorders; synthetically developed therapeutic agents for antimicrobial or acute cardiovascular use	77/282195 18 Sep 2007	11 Mar 2008	3538219 25 Nov 2008	Registered 25 Nov 2018
PACE* United States	Class: 42 Int. - Providing on-line non-downloadable computer software for use in the research and development of therapeutic drug preparations	77/611107 10 Nov 2008	24 Mar 2009	3729727 22 Dec 2009	Registered 22 Dec 2019
POLYCID* United States	Class: 05 Int. - Antimicrobial preparations, blends and formulations of oligomers and small molecules used to treat, eliminate and/or reduce the growth of bacteria and fungus on various surfaces	85/438721 04 Oct 2011	10 Jan 2012	4118719 27 Mar 2012	Registered 27 Mar 2022
POLYCID* United States	Class: 05 Int. - Antimicrobial preparations, blends and formulations of polymers used to treat, eliminate and/or reduce the growth of bacteria and fungus on various surfaces	77/767319 24 Jun 2009	26 Jan 2010	3887304 07 Dec 2010	Registered 07 Dec 2020

<u>Trademark/ Country</u>	<u>Goods</u>	<u>Application Number/Date</u>	<u>Publication Number/Date</u>	<u>Registration Number/Date</u>	<u>Status/ Next Renewal</u>
POLYDENTIX* United States	Class: 05 Int. - Preparations and agents for dental use, namely, therapeutic antimicrobial preparations, biotechnologically and synthetically developed therapeutic agents and for antimicrobial agents	77/190615 25 May 2007	13 May 2008	4063543 29 Nov 2011	Registered 29 Nov 2021
POLYDENTIX* United States	Class: 05 Int. - Preparations and agents for dental use, namely therapeutic antimicrobial preparations, biotechnologically and synthetically developed therapeutic agents and for antimicrobial agents	85/388529 03 Aug 2011			Pending
POLYMEDIX* United States	Class: 05 Int. - Therapeutic preparations interacting with cellular membranes or proteins, namely, for use in treating antimicrobial and cardiac diseases or disorders, synthetically developed therapeutic agents for antimicrobial or acute cardiovascular use	77/188350 23 May 2007	04 Dec 2007	3401024 25 Mar 2008	Registered 25 Mar 2018
SUCCEED* United States	Class: 42 Int. - Providing on-line non-downloadable computer software for use in the research and development of therapeutic drug preparations	77/611118 10 Nov 2008	24 Mar 2009	3729728 22 Dec 2009	Registered 22 Dec 2019